Life Sciences 2025

GREECE Law and Practice Contributed by: Angela Livgieri, Danai Panopoulou and Iliana Andronou, ALG Manousakis Law Firm

stance from the drugs listed in the positive list unless the consumer insists on a brand-name drug and pays the price difference in addition to a co-payment which is typically 0%-25% of the drug cost. Also, pharmacies are linked to the national e-prescription system, ensuring real-time track- ing. Law 4052/2012, as amended, provides for a claw-back mechanism imposing a specific budget for pharmaceutical sales to public health- care entities. As a result, any amount exceeding the budget is recovered by the payors from the MAHs of pharmaceutical products.

141 CHAMBERS.COM

Powered by